Hogan Lovells Digital Health brochure 2024 - Flipbook - Page 5
Hogan Lovells has also been involved in
a wide variety of transactions, helping
clients to leverage developments
in arti昀椀cial intelligence and the life
sciences. Whilst developments in AI are
seeing novel and exciting collaborations
between pharma and the computer
sciences, we understand that such
collaborations can require bespoke
arrangements to deal with, among
other things, the data being inputted
into the AI and the allocation of rights
produced by the AI.
In addition, Hogan Lovells has been
at the forefront of medical device
arti昀椀cial intelligence regulation. We
have advised our clients on the clearance
and approval of numerous medical
devices that incorporate AI algorithms.
These technologies have demonstrated
enormous potential for health care,
while at the same time raising unique
regulatory questions due to their
iterative and potentially self-updating
nature, which is incongruent with
historical regulatory approaches.
5
